Trillium Therapeutics (TRIL)
In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Trillium Therapeutics. The company’s shares opened today at $6.15, close to its 52-week low of $4.75.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 13.8% and a 48.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on Trillium Therapeutics is a Moderate Buy with an average price target of $10.
Bausch Health Companies Inc (BHC)
In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Bausch Health Companies Inc, with a price target of $35. The company’s shares opened today at $22.56.
Rivkind Koffler observed:
“We believe investor expectations were for a “mid-twenties” generic launch, so the 2028 settlement is more favorable than expected. This update removes a key overhang on the stock, in our view. We reiterate our Buy rating and $35 PT.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 11.8% and a 46.7% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Pacira Pharmaceuticals, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Bausch Health Companies Inc is a Hold with an average price target of $25.25, an 11.9% upside from current levels. In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $32 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.